Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02038036
Title Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

polycythemia vera

Therapies

Peginterferon alfa-2b

Anagrelide

Hydroxyurea

Pipobroman

Ruxolitinib

Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.